Casebia Therapeutics, a three-year old start-up in the hotly contested gene therapy space, is the product of a remarkably relaxed joint venture between the German multinational giant Bayer and CRISPR Therapeutics, a leader in conducting the first clinical trial involving the CRISPR-Cas9 editing platform.
Rarely has any big pharma-biotech joint venture been so strategic – and so generous – in grafting existing expertise onto a start-up, from the ground up. And Bayer has gained some welcome protection against the distractions of the company’s recent – and controversial – diversification into lines of business beyond patented medicines.
Jim Burns, CEO of Casebia Therapeutics, expects the company’s first Investigational New Drug (IND) filing with the FDA to...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Exec summary XXXXXXX
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
